Annual Report 2021
Interim report Q1 2024
Annual Report 2023
Interim report Q1 2023
Interim report Q2 2023
Interim report Q3 2023
Year-end report Q4 2023
Annual Report 2022
Interim report Q1 2022
Interim report Q2 2022
Interim report Q3 2022
Year-end Report Q4 2022
Annual Report 2021
Delårsrapport Q1 2021
Delårsrapport Q2 2021
Delårsrapport Q3 2021
Year-end report Q4 2021
Årsredovisning 2020
Older reports
2024
2023
2022
2021
2020
The Business
The Business
The year in short
Comments by the CEO
Business Model
AddLife´s DNA
Strategy
Financial targets
Market
Business Area Labtech
Business Area Medtech
Acquisitions
The Share
Four reasons to own AddLife
Sustainability
Sustainability
Our focus on sustainability
Our role in the value chain
Governance
Responsible producer and distributor
Responsible employer
AddLife Academy
Responsible market participant
Materiality assessment
EU Taxonomy report 2021
Administration Report
Administration Report
Acquisitions
Financial development during the year
Dividend
Risks and uncertainties
Remuneration
Employees, research and development and environment
Parent company
Corporate Governance
Corporate Governance
Board of Directors
Group management
General Meeting
Annual General Meeting 2022
Internal control
Nomination Committee
Audit
Financial Information
Financial Information
Group
Consolidated Income Statement
Consolidated statement of comprehensive income
Consolidated Balance Sheet
Consolidated statement of changes in equity
Consolidated statement of cash flows
Parent company
Parent Company Income Statement
Parent Company Statement of comprehensive income
Parent Company Balance Sheet
Parent Company Statement of Cash Flows
Parent Company Statement of Changes in Equity
Notes
The share
Key ratios
Major shareholders
Class sizes
Holdings per category
Assurance of the Board of Director
Auditor's report
Multi-year overview
Definitions
Search for:
AddLife´s DNA
Latest updated: 12/10/2021 11:57:43 AM by Alexander Paziraei
NEXT
